<?xml version="1.0" encoding="UTF-8"?>

<ValueSet xmlns="http://hl7.org/fhir">
  <id value="AntibioticSensitivityInterpretation"/>
  <text>
    <status value="extensions"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ValueSet AntibioticSensitivityInterpretation</b></p><a name="AntibioticSensitivityInterpretation"> </a><a name="hcAntibioticSensitivityInterpretation"> </a><a name="AntibioticSensitivityInterpretation-en-US"> </a><ul><li>Include these codes as defined in <a href="http://terminology.hl7.org/6.3.0/CodeSystem-v3-ObservationInterpretation.html"><code>http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretation</code></a><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td><a href="http://terminology.hl7.org/6.3.0/CodeSystem-v3-ObservationInterpretation.html#v3-ObservationInterpretation-I">I</a></td><td>Intermediate</td><td>Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2<br/><br/>\[Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.\]<br/><br/>\[Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.\]<br/><br/>\[Note 3: This class also indicates a &quot;buffer zone,&quot; to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.\]<br/><br/>\[Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]</td></tr><tr><td><a href="http://terminology.hl7.org/6.3.0/CodeSystem-v3-ObservationInterpretation.html#v3-ObservationInterpretation-R">R</a></td><td>Resistant</td><td>Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2<br/><br/>\[Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.\]<br/><br/>\[Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]</td></tr><tr><td><a href="http://terminology.hl7.org/6.3.0/CodeSystem-v3-ObservationInterpretation.html#v3-ObservationInterpretation-S">S</a></td><td>Susceptible</td><td>Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2<br/><br/>\[Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.\]<br/><br/>\[Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]</td></tr><tr><td><a href="http://terminology.hl7.org/6.3.0/CodeSystem-v3-ObservationInterpretation.html#v3-ObservationInterpretation-SYN-S">SYN-S</a></td><td>Synergy - susceptible</td><td>A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective.<br/><br/>*Usage Note:* Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.<br/><br/>*Open Issue:* The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.</td></tr><tr><td><a href="http://terminology.hl7.org/6.3.0/CodeSystem-v3-ObservationInterpretation.html#v3-ObservationInterpretation-SYN-R">SYN-R</a></td><td>Synergy - resistant</td><td>A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective.<br/><br/>*Usage Note:* Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.<br/><br/>*Open Issue:* The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.</td></tr></table></li></ul></div>
  </text>
  <url value="http://va.gov/fhir/ValueSet/AntibioticSensitivityInterpretation"/>
  <version value="1.5.11"/>
  <name value="AntibioticSensitivityInterpretation"/>
  <title value="AntibioticSensitivityInterpretation FHIR"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2025-05-08T08:54:46+00:00"/>
  <publisher value="VA"/>
  <contact>
    <name value="VA"/>
    <telecom>
      <system value="url"/>
      <value value="https://www.va.gov"/>
    </telecom>
  </contact>
  <description value="FHIR Target ValueSet for Terminology Maps [VF_AntibioticSensitivityInterpretation](ConceptMap-VF-AntibioticSensitivityInterpretation.html)"/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="US"/>
      <display value="United States of America"/>
    </coding>
  </jurisdiction>
  <compose>
    <include>
      <system value="http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretation"/>
      <concept>
        <code value="I"/>
        <display value="Intermediate"/>
      </concept>
      <concept>
        <code value="R"/>
        <display value="Resistant"/>
      </concept>
      <concept>
        <code value="S"/>
        <display value="Susceptible"/>
      </concept>
      <concept>
        <code value="SYN-S"/>
        <display value="Synergy - susceptible"/>
      </concept>
      <concept>
        <code value="SYN-R"/>
        <display value="Synergy - resistant"/>
      </concept>
    </include>
  </compose>
</ValueSet>